Table 2.
Prognostic scores in HFrEF vs. cancer.
| Prognostic scores/ratios |
HFrEF study population
(n = 443) |
Oncologic study population
(n = 375) |
p-value |
|---|---|---|---|
| NLR, –(IQR) | 3.8 (2.6–5.7) | 3.3 (2.1–5.4) | 0.001 |
| MLR, –(IQR) | 0.5 (0.4–0.7) | 0.4 (0.3–0.6) | <0.001 |
| PLR, –(IQR) | 145 (110–202) | 179 (129–269) | <0.001 |
| PNI, –(IQR) | 65 (46–86) | 58 (40–81) | 0.002 |
MLR, monocyte-to-lymphocyte ratio; NRI, nutritional risk index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio, PNI, prognostic nutritional index.